ロード中...

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

We observed a 53% response rate in non-small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibition was assessed in NSCLC cells by MTT assay after 7...

詳細記述

保存先:
書誌詳細
主要な著者: Owonikoko, Taofeek K., Ramalingam, Suresh S., Kanterewicz, Beatriz, Balius, Trent, Belani, Chandra P., Hershberger, Pamela A.
フォーマット: Artigo
言語:Inglês
出版事項: 2010
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2795066/
https://ncbi.nlm.nih.gov/pubmed/19621389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.24759
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!